Drug Monograph

Drug/Drug Class: **Nascobal™ (cyanocobalamin) nasal spray / Vitamin B_{12} supplement**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Each unit dose of Nascobal™ contains 500 mcg of cyanocobalamin per spray.
Manufacturer:	Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977 USA
Indications:	Nascobal™ is a vitamin B_{12} supplement indicated for the maintenance/treatment of pernicious anemia following intramuscular supplementation, dietary cyanocobalamin deficiency, malabsorption of cyanocobalamin, gastric atrophy associated with inadequate secretion of intrinsic factor, competition for and inadequate utilization of cyanocobalamin.
Costs:	$90.28 per weekly unit dose of Nascobal™ WholesaleAcquisitionCost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	☐ Prior Authorization (PA) Required ☒ Open Access ☐ Fiscal Edit ☐ Clinical Edit
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☐ Appropriate Indications ☒ No PA Required

Prepared By: Abbey Mahaney, Pharm. D. Candidate 2015
Date: November 2, 2014

© 2014 Xerox Heritage, LLC All Rights Reserved.